Dermata Therapeutics (DRMA) Short Interest Ratio & Short Volume $0.77 0.00 (-0.29%) Closing price 03:57 PM EasternExtended Trading$0.76 -0.01 (-0.91%) As of 07:17 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Short Interest Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock Dermata Therapeutics Short Interest DataDermata Therapeutics (DRMA) has a short interest of 255,100 shares, representing 5.76% of the float (the number of shares available for trading by the public). This marks a 110.83% increase in short interest from the previous month. The short interest ratio (days to cover) is 0.2, indicating that it would take 0.2 days of the average trading volume of 1.17 million shares to cover all short positions.Current Short Interest255,100 sharesPrevious Short Interest121,000 sharesChange Vs. Previous Month+110.83%Dollar Volume Sold Short$213,824.82Short Interest Ratio0.2 Days to CoverLast Record DateApril 30, 2025Outstanding Shares6,378,000 sharesFloat Size4,430,000 sharesShort Percent of Float5.76%Today's Trading Volume30,077 sharesAverage Trading Volume1,173,853 sharesToday's Volume Vs. Average3% Short Selling Dermata Therapeutics? Sign up to receive the latest short interest report for Dermata Therapeutics and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartDRMA Short Interest Over TimeDRMA Days to Cover Over TimeDRMA Percentage of Float Shorted Over Time Dermata Therapeutics Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 4/30/2025255,100 shares $213,824.82 +110.8%5.8%0.2 $0.84 4/15/2025121,000 shares $94,246.90 -84.3%2.7%0.1 $0.78 3/31/2025770,100 shares $831,708.00 +307.9%19.3%0.5 $1.08 3/15/2025188,800 shares $224,672.00 -23.8%4.7%0.5 $1.19 2/28/2025247,700 shares $282,378.00 -10.9%15.2%0.5 $1.14 2/15/2025278,000 shares $330,820.00 -5.5%44.9%0.6 $1.19 1/31/2025294,200 shares $361,866.00 +112.9%47.5%0.6 $1.23 1/15/2025138,200 shares $192,098.00 -3.3%15.7%0.3 $1.39 12/31/2024142,900 shares $192,915.00 +11.3%7.1%0.5 $1.35 12/15/2024128,400 shares $139,956.00 +125.7%6.4%0.4 $1.09 Get the Latest News and Ratings for DRMA and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Dermata Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 11/30/202456,900 shares $64,183.20 -36.9%2.9%0.1 $1.13 11/15/202490,200 shares $101,033.02 -3.7%6.1%0.2 $1.12 10/31/202493,700 shares $118,999.00 +228.8%6.3%0.2 $1.27 10/15/202428,500 shares $36,765.00 -58.8%1.9%0 $1.29 9/30/202469,100 shares $113,324.00 +558.1%4.7%0 $1.64 9/15/202410,500 shares $16,590.00 -53.5%0.7%0 $1.58 8/31/202422,600 shares $39,324.00 -49.9%1.8%0 $1.74 8/15/202445,100 shares $92,906.00 -12.9%3.6%0 $2.06 7/31/202451,800 shares $89,096.00 -1.5%8.0%0 $1.72 7/15/202452,600 shares $115,194.00 +141.3%8.1%0 $2.19 6/30/202421,800 shares $52,102.00 +6.9%3.4%0.6 $2.39 6/15/202420,400 shares $52,073.04 -20.0%4.9%0.7 $2.55 5/31/202425,500 shares $97,920.00 +318.0%6.1%1.5 $3.84 5/15/20246,100 shares $30,195.00 -92.4%1.5%0.4 $4.95 4/30/202480,400 shares $26,298.84 +3.6%1.3%0.7 $0.33 4/15/202477,600 shares $23,295.52 -23.8%1.2%0.5 $0.30 3/31/2024101,800 shares $41,819.44 +42.6%1.7%0.2 $0.41 3/15/202471,400 shares $28,417.20 -0.8%2.1%0.1 $0.40 2/29/202472,000 shares $33,048.00 -57.5%2.5%0.1 $0.46 2/15/2024169,500 shares $78,817.50 -39.3%6.0%0.2 $0.47 1/31/2024279,400 shares $137,045.70 -5.5%9.9%0.3 $0.49 1/15/2024295,600 shares $159,328.40 +1,032.6%10.5%0.3 $0.54 12/31/202326,100 shares $15,921.00 -25.9%0.9%0 $0.61 12/15/202335,200 shares $23,936.00 -67.7%1.3%0.2 $0.68 11/30/2023108,800 shares $81,099.52 +57.7%3.9%0.5 $0.75 11/15/202369,000 shares $44,988.00 +156.5%2.5%0.2 $0.65 10/31/202326,900 shares $15,653.11 -34.6%1.0%0.2 $0.58 10/15/202341,100 shares $30,825.00 -42.3%1.5%0.3 $0.75 9/30/202371,200 shares $75,472.00 -29.1%2.6%0.5 $1.06 9/15/2023100,400 shares $117,468.00 +16,633.3%3.6%0.6 $1.17A grave, grave error. (Ad)I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again. Here’s the full story for you. 8/31/2023600 shares $744.00 -95.8%0.0%0 $1.24 8/15/202314,400 shares $16,992.00 -10.0%0.5%0.1 $1.18 7/31/202316,000 shares $20,800.00 -66.3%0.8%0 $1.30 7/15/202347,500 shares $74,575.00 -42.5%2.3%0.1 $1.57 6/30/202382,600 shares $136,290.00 +17.5%4.0%0 $1.65 6/15/202370,300 shares $130,055.00 +221.0%3.6%0 $1.85 5/31/202321,900 shares $35,040.00 -68.5%1.7%0 $1.60 5/15/202369,600 shares $179,568.00 +10.3%4.1%0 $2.58 4/30/202363,100 shares $103,484.00 +248.6%0.7%0 $1.64 4/15/202318,100 shares $22,806.00 -40.9%0.2%0 $1.26 3/31/202330,600 shares $39,474.00 +155.0%0.4%0 $1.29 3/15/202312,000 shares $33,840.00 -93.8%0.2%0 $2.82 2/28/2023194,000 shares $50,440.00 -0.2%2.4%0.1 $0.26 2/15/2023194,400 shares $56,084.40 -42.2%2.4%0.1 $0.29 1/31/2023336,100 shares $92,057.79 +36.2%4.2%0.2 $0.27 1/15/2023246,800 shares $67,277.68 +121.0%3.1%0.1 $0.27 12/30/2022111,700 shares $45,685.30 -5.7%1.4%0.1 $0.41 12/15/2022118,500 shares $23,024.55 +8.2%1.5%0.2 $0.19 11/30/2022109,500 shares $70,616.55 -25.8%1.5%0.4 $0.64 11/15/2022147,600 shares $98,892.00 -18.6%2.1%0.6 $0.67 10/31/2022181,300 shares $119,748.65 +129.5%3.0%0.5 $0.66 10/15/202279,000 shares $56,090.00 +62.6%1.3%0.2 $0.71 9/30/202248,600 shares $25,276.86 +21.5%0.8%0.1 $0.52 9/15/202240,000 shares $25,672.00 -54.3%0.7%0 $0.64 8/31/202287,500 shares $49,875.00 +154.4%1.6%0.1 $0.57 8/15/202234,400 shares $23,392.00 -52.6%0.6%0 $0.68 7/31/202272,600 shares $42,195.12 +30.3%1.6%0.1 $0.58 7/15/202255,700 shares $41,218.00 -78.6%1.2%0 $0.74 6/30/2022260,000 shares $169,026.00 +3,413.5%5.6%0.2 $0.65 6/15/20227,400 shares $3,981.20 -82.6%0.2%0.1 $0.54 5/31/202242,600 shares $33,236.52 +138.0%1.0%0.4 $0.78 5/15/202217,900 shares $14,749.60 -53.0%0.4%0.2 $0.82 4/30/202238,100 shares $39,243.00 -85.4%0.9%0.1 $1.03 4/15/2022261,400 shares $299,303.00 -15.5%6.1%0.5 $1.15 3/31/2022309,500 shares $386,875.00 +1.1%N/A0.5 $1.25 3/15/2022306,200 shares $286,358.24 -23.1%7.0%0.5 $0.94 2/28/2022398,000 shares $489,540.00 -48.2%9.2%0.7 $1.23 2/15/2022768,100 shares $898,677.00 +477.5%17.7%1.3 $1.17 1/31/2022133,000 shares $299,250.00 +56.7%3.1%0.6 $2.25 1/15/202284,900 shares $131,595.00 +69.5%N/A0.3 $1.55 12/31/202150,100 shares $87,174.00 No Change1.2%0.2 $1.74 DRMA Short Interest - Frequently Asked Questions What is Dermata Therapeutics' current short interest? Short interest is the volume of Dermata Therapeutics shares that have been sold short but have not yet been covered or closed out. As of April 30th, traders have sold 255,100 shares of DRMA short. 5.76% of Dermata Therapeutics' shares are currently sold short. Learn More on Dermata Therapeutics' current short interest. What is a good short interest percentage for Dermata Therapeutics? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 5.76% of Dermata Therapeutics' floating shares are currently sold short. Is Dermata Therapeutics' short interest increasing or decreasing? Dermata Therapeutics saw a increase in short interest in the month of April. As of April 30th, there was short interest totaling 255,100 shares, an increase of 110.8% from the previous total of 121,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. What is Dermata Therapeutics' float size? Dermata Therapeutics currently has issued a total of 6,378,000 shares. Some of Dermata Therapeutics' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Dermata Therapeutics currently has a public float of 4,430,000 shares. How does Dermata Therapeutics' short interest compare to its competitors? 5.76% of Dermata Therapeutics' shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical products" compare to Dermata Therapeutics: Passage Bio, Inc. (3.42%), VYNE Therapeutics Inc. (1.57%), Lexaria Bioscience Corp. (3.26%), Chemomab Therapeutics Ltd. (0.74%), AlloVir, Inc. (2.56%), Allarity Therapeutics, Inc. (10.88%), TherapeuticsMD, Inc. (1.04%), Bullfrog AI Holdings, Inc. (6.00%), GlycoMimetics, Inc. (2.84%), ProMIS Neurosciences, Inc. (0.99%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: Spotify Technology S.A. ($4.67 billion), Charter Communications, Inc. ($4.58 billion), Capital One Financial Co. ($4.47 billion), The Kroger Co. ($2.56 billion), Reddit, Inc. ($2.23 billion), Rivian Automotive, Inc. ($2.16 billion), Live Nation Entertainment, Inc. ($1.90 billion), SoFi Technologies, Inc. ($1.85 billion), Zscaler, Inc. ($1.75 billion), and Omnicom Group Inc. ($1.75 billion). View all of the most shorted stocks. What does it mean to sell short Dermata Therapeutics stock? Short selling DRMA is an investing strategy that aims to generate trading profit from Dermata Therapeutics as its price is falling. DRMA shares are trading down $0.00 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Dermata Therapeutics? A short squeeze for Dermata Therapeutics occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of DRMA, which in turn drives the price of the stock up even further. How often is Dermata Therapeutics' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including DRMA, twice per month. The most recent reporting period available is April, 30 2025. More Short Interest Resources from MarketBeat Related Companies Passage Bio Short Squeeze VYNE Therapeutics Short Squeeze Lexaria Bioscience Short Squeeze Chemomab Therapeutics Short Squeeze AlloVir Short Squeeze Allarity Therapeutics Short Squeeze TherapeuticsMD Short Squeeze Bullfrog AI Short Squeeze GlycoMimetics Short Squeeze ProMIS Neurosciences Short Squeeze Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:DRMA) was last updated on 5/22/2025 by MarketBeat.com Staff From Our PartnersWatch This Robotics Demo Before July 23rdJeff Brown, the tech legend who picked shares of Nvidia in 2016 before they jumped by more than 22,000%... ...Brownstone Research | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredTrump Predicts Dollar DownfallREAD THIS VERY CAREFULLY: If you have $100,000 or more saved for retirement, this may make you VERY angry... ...Augusta Precious Metals | SponsoredThe Secret Map of America, Declassified…Locked inside a Maryland man’s private safe is a map. But not just any map, mind you… This map shows a “...Banyan Hill Publishing | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredSilver Is the New Oil—And the World’s Running DryElon's Next Market Move Could Send Silver Soaring Every industry Elon Musk touches explodes—from Tesla to S...Priority Gold | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Dermata Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Dermata Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
